GPT and Hepatic fibrosis: By utilizing fibrosis as a surrogate endpoint over a defined 3‐year timeframe, TORCH‐B provided clinical evidence that antiviral therapy lowers the risk of progression in liver fibrosis among those with viremia and minimally elevated ALT.57